Loading...

The Value of EGFRvIII as the Target for Glioma Vaccines

Malignant brain tumors continue to be rapidly progressive and resistant to most treatments. Even with state-of-the-art standard of care (surgery, chemotherapy, and radiotherapy) long-term survival in the last 80 years improved from 6 to 15 months. Improved imaging has also likely contributed to prol...

Full description

Saved in:
Bibliographic Details
Published in:Am Soc Clin Oncol Educ Book
Main Authors: Lowenstein, Pedro R., Castro, Maria G.
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4438702/
https://ncbi.nlm.nih.gov/pubmed/24857059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14694/EdBook_AM.2014.34.42
Tags: Add Tag
No Tags, Be the first to tag this record!